BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai has notified BioArctic that the first sales milestone according to the licensing agreement has been reached. The milestone was reached as ...

BioArctic AB's (publ) partner Eisai has notified BioArctic that the first sales milestone according to the licensing agreement has been reached. The milestone was reached as sales of Leqembi reached ?

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai has notified BioArctic that the first sales milestone according to the licensing agreement ...

"We are now, within short, ready to initiate the phase 2b study - with the goal of making fostrox + Lenvima the first approved medical treatment for second-line liver cancer" October - DecemberFinanci ...

Patients with localized muscle-invasive bladder cancer (MIBC) who received radiation plus the immune checkpoint inhibitors ...

New treatments can slow the disease’s progress, which is why the Alzheimer’s Association is leveraging its celebrity partners ...

Newly published detailed clinical trial data show why Exelixis abandoned a plan to seek an FDA approval for a combination of ...

VIVOZON Pharmaceutical announced that its non-opioid analgesic, UNAFRA Inj., was approved on December 12, 2024. (Active ...

Liver Cancer Therapeutics Market Growth is Driven by Advancements in Precision Medicine, Immunotherapy and Growing Global Incidence.Pune, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Liver Cancer Therapeutics ...

This is the first and only conference exclusively focusing on ADC payloads, helping you to reimagine the medicinal chemistry of ...